Like so many stakeholders in the healthcare community and in the government, we share the desire to address the serious national challenge related to the misuse and abuse of opioids that has led to addiction and unnecessary deaths and has caused so much pain to families and communities around the country.
Consistent with our management team’s sincere commitment to conduct business according to high ethical standards and the best interests of patients, we also have taken and will continue to strive to take measures to ensure that sound compliance protocols underpin our business practices. Furthermore, we intend to continue working collaboratively and constructively with all relevant authorities to resolve our outstanding governmental investigations.
Concurrently, we remain committed to focusing on patients by delivering on the promise of our approved and potential pipeline products for their appropriate indications, which address a variety of serious and unmet patient needs. In this regard, INSYS has invested more than
With respect to the recently filed
- Launched in 2012, SUBSYS® (fentanyl sublingual spray) accounted for a fractional percentage (less than 0.02 percent) of opioid prescriptions nationally.
- In 2015, the year of highest utilization for SUBSYS, there were about 9,200 patients who were prescribed the product versus approximately 52 million patients who were prescribed opioids in
the United States. This represents less than 0.018 percent.
- The figures are similar for
New York, where approximately 2.23 million patients were prescribed opioids in 2015, of which 680 patients or 0.03 percent were prescribed SUBSYS. In 2017, SUBSYS patients were 0.0065 percent of the total patients prescribed opioids in New York.
Accordingly, we do not believe it is factually accurate to link INSYS with materially contributing to the opioid crisis in the
|CONTACT:||Corporate Communications||Investor Relations|
|Joe McGrath||Jackie Marcus or Chris Hodges|
|INSYS Therapeutics||Alpha IR Group|